Americord Supports Delayed Cord Clamping


Cord Blood Bank Endorses Recommendation by American College of Obstetrics and Gynecology for Delayed Cord Clamping and Cord Blood Banking

Americord Registry announced today that it endorses the practice of delayed cord clamping following the recommendations by the American College of Obstetrics and Gynecology (ACOG).The ACOG recommends that parents who choose to delay cord clamping do so for at least 90 seconds and no more than three minutes following birth. This time frame helps to ensure that the child receives the benefits of the cord blood while still saving enough stem cells for a cord blood collection. When the cord blood collection is begun no later than three minutes, the chances of a viable collection size are high.“With new research into delayed cord clamping and its many benefits, more parents are considering this practice,” says Americord CEO Martin Smithmyer. “We want parents to know that delayed cord clamping and cord blood banking are both possible, following the recommendations by the ACOG.”

Current industry benchmarks for cord blood collections are a minimum of 100 million cells. Given the amount of blood likely to flow out of the placenta at the time of birth, there is typically plenty to be stored for later use. Americord is also the only cord blood bank to offer Cord Blood 2.0™, which allows parents to collect up to twice as many stem cells as the industry standard. Now that it is possible to collect twice as many stem cells, parents can do a cord blood collection after delayed cord clamping that results in a viable collection size and volume while still providing their child with the health benefits of delayed cord clamping.

About Americord Registry

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratory is CLIA Certified, and complies with all federal and state, and AABB guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry’s website at for more information.

Cyber Monday Sale